My Cancer Genome contains assertions on the clinical impact of 16,871 molecular biomarkers on the use of 2,861 drugs in 955 cancer types. This information is derived from FDA labels, NCCN and other professional society guidelines, 9,809 clinical trials, peer-reviewed publications, and more. Biomarker prevalence is illustrated using data from 96,324 tumor samples and 89,356 patients in the AACR Project GENIE database.
Learn About My Cancer Genome